Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PBF-999 in advanced solid tumors
NCT03786484Phase 1Completed
- Sponsor
- Palobiofarma
- Start
- Oct 2017
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of PBF-999 in solid tumor (advanced stage) (5 arms), sponsored by Palobiofarma. Primary endpoints: Number of Adverse Events (AEs) at 28 Days and Maximum Tolerated Dose at 28 Days. Started Oct 2017; status: completed.
02
Drugs
PBF-999
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03786484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03786484.